Aclaris Therapeutics, Inc.
Every calculator, already run for ACRS
Open the full toolkit →You have the numbers on ACRS. Get the argument.
A written report on which of these readings actually decide the outcome for Aclaris Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
10 analysts covering ACRSOwnership & short interest
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-I…
ACRS — frequently asked
Is ACRS a buy right now?
Wall Street's consensus rating on Aclaris Therapeutics, Inc. is Strong Buy across 10 analysts, with a mean price target of $10.00 (+61% vs. the current $6.21). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ACRS's next earnings date?
Aclaris Therapeutics, Inc. is next scheduled to report earnings around Aug 6, 2026. A full ACRS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
Compare Aclaris Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Aclaris Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ACRS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Aclaris Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.